Some neurons stand out in the crowd. Researchers report that genomic variation among neurons in the brain is more common than originally thought.
Tau fragments in cerebrospinal fluid might lead to better prognostic and diagnostic tests.
Stacked together, amyloid subunits absorb more light than they do as monomers. Are there implications for fibril detection?
Phase 3 trial results suggest pimavanserin tempers psychosis in people with Parkinson’s.
New regulatory initiatives will soon make clinical trial data more publicly available than ever, but industry and other groups warn that the move could endanger patient privacy and lead to misuse of data.
The latest news on C9ORF72 includes a genetic modifier, various animal models, and a potential treatment to untangle stable, guanine-based structures formed by expanded repeats.
A proof-of-concept study suggests that amyloid imaging will offer insights into traumatic brain injury.
Researchers find an actin-binding protein in stress granules, linking the cytoskeleton and RNA sequestration in the pathology of amyotrophic lateral sclerosis.
A mouse with TDP-43 proteinopathy looks to be an unlikely model for testing amyotrophic lateral sclerosis drugs.
The FDA has approved a second tracer, flutemetamol, for PET imaging of amyloid plaques in the brain.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.